Key Highlights: Implications: Emcure is effectively repositioning Poviztra as a mass‑market GLP‑1 for obesity in India, using a steep 55% entry‑dose cut (now ₹3,999/mon...
Key Highlights: Implications: Extensior catapults Abbott into the GLP-1 frenzy, grabbing prime shelf space before generics from Eris/Natco crash prices by half—think explosive Tier-2 growt...
